Clover Health Investments, Corp vs Merck & Company, Inc. — Stock Comparison
Clover Health Investments, Corp (CLOV) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. narrowly edges Clover Health Investments, Corp on Q·Score (6 vs 5.9 out of 10), led by Sentiment (7.2 vs 6.2) and Health (7 vs 6.1). Clover Health Investments, Corp scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for CLOV (+23.3%) than for MRK (+6.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Revenue expanding at 56% year-over-year.
⚠ currently unprofitable (-1% margin).
68% of 28 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
Analyst Consensus
Fundamentals
Frequently Asked Questions
CLOV vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 6/10 versus Clover Health Investments, Corp (CLOV) at 5.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: CLOV or MRK?
Clover Health Investments, Corp (CLOV) scores higher on Growth (7.1/10 vs 5.1/10). Clover Health Investments, Corp reports revenue growth (55.6% YoY) while Merck & Company, Inc. reports (4.7% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is CLOV or MRK more attractively valued?
Clover Health Investments, Corp (CLOV) scores higher on Valuation (7/10 vs 7/10). CLOV trades at 29.7× P/E versus MRK at 16.2×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about CLOV vs MRK?
There are 5 analysts covering CLOV with a consensus price target of $5.50, and 26 analysts covering MRK with a consensus target of $159.60. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: CLOV or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (4.4/10 vs 3.7/10). Net profit margin: CLOV at -0.7%, MRK at 3.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: CLOV or MRK?
Merck & Company, Inc. (MRK) scores higher on Financial Health (7/10 vs 6.1/10). Market beta: CLOV at 2.46, MRK at N/A. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of CLOV and MRK?
Clover Health Investments, Corp (CLOV) has a market capitalisation of $2.4B, while Merck & Company, Inc. (MRK) has a market cap of $368.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do CLOV or MRK pay dividends?
CLOV does not currently pay a dividend, while MRK pays a dividend yield of 2.32%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →